Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2018

Open Access 01-12-2018 | Review

Emerging roles of long non-coding RNAs in tumor metabolism

Authors: Hui Sun, Zhaohui Huang, Weiqi Sheng, Mi-die Xu

Published in: Journal of Hematology & Oncology | Issue 1/2018

Login to get access

Abstract

Compared with normal cells, tumor cells display distinct metabolic characteristics. Long non-coding RNAs (lncRNAs), a large class of regulatory RNA molecules with limited or no protein-coding capacity, play key roles in tumorigenesis and progression. Recent advances have revealed that lncRNAs play a vital role in cell metabolism by regulating the reprogramming of the metabolic pathways in cancer cells. LncRNAs could regulate various metabolic enzymes that integrate cell malignant transformation and metabolic reprogramming. In addition to the known functions of lncRNAs in regulating glycolysis and glucose homeostasis, recent studies also implicate lncRNAs in amino acid and lipid metabolism. These observations reveal the high complexity of the malignant metabolism. Elucidating the metabolic-related functions of lncRNAs will provide a better understanding of the regulatory mechanisms of metabolism and thus may provide insights for the clinical development of cancer diagnostics, prognostics and therapeutics.
Literature
1.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat RevCancer. 2011;11(2):85–95.CrossRef
2.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY). 2009;324(5930):1029–33.CrossRef
3.
Newsholme EA, Crabtree B, MSM A. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Bioscience. 1985;5:393–400.CrossRef
4.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.PubMedCrossRef
5.
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. General Physiology. 1926;8(6):519–30.CrossRef
6.
Warburg O, Posener K, Negelein E. Uber den Stoffwechsol der Carcinomzelle. Eingegangen. 1924;6:310–44.
7.
Li L, Kang L, Zhao W, Feng Y, Liu W, Wang T, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. Cancer Lett. 2017;400:89–98.PubMedCrossRef
8.
Chen Z, Liu M, Li L, Chen L. Involvement of the Warburg effect in non-tumor diseases processes. J Cell Physiol. 2018;233(4):2839–49.PubMedCrossRef
9.
10.
DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313–24.PubMedCrossRef
11.
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–84.PubMedPubMedCentralCrossRef
12.
13.
Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med. 2011;52(7):1005–8.PubMedCrossRef
14.
Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–94.PubMedCrossRef
15.
Lamonte G, Tang X, Chen JL, Wu J, Ding CK, Keenan MM, et al. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab. 2013;1(1):23.PubMedPubMedCentralCrossRef
16.
Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 2010;6(4):e1000899.PubMedPubMedCentralCrossRef
17.
18.
Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–70.PubMedPubMedCentralCrossRef
19.
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.PubMedCrossRef
20.
21.
Perkel JM. Visiting “Noncodarnia”. BioTechniques. 2016;54:301–4.
22.
Wang ZH, Guo XQ, Zhang QS, Zhang JL, Duan YL, Li GF, et al. Long non-coding RNA CCAT1 promotes glioma cell proliferation via inhibiting microRNA-410. Biochem Biophys Res Commun. 2016;480(4):715–20.PubMedCrossRef
23.
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6:23892.PubMedPubMedCentralCrossRef
24.
25.
Yang SZ, Xu F, Zhou T, Zhao X, McDonald JM, Chen Y. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. J Biol Chem. 2017;292(25):10390–7.PubMedPubMedCentralCrossRef
26.
Cao MX, Jiang YP, Tang YL, Liang XH. The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget. 2016;8:12472–83.PubMedCentral
27.
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by non-coding RNAs. Cell. 2007;129(7):1311–23.
28.
Li H, Ma SQ, Huang J, Chen XP, Zhou HH. Roles of long noncoding RNAs in colorectal cancer metastasis. Oncotarget. 2017;8(24):39859–76.PubMedPubMedCentral
29.
Zhu X, Wu YB, Zhou J, Kang DM. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression. Biochem Biophys Res Commun. 2016;469(2):319–25.PubMedCrossRef
30.
Ellis BC, Graham LD, Molloy PL. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta. 2014;1843(2):372–86.PubMedCrossRef
31.
32.
Li HJ, Li X, Pang H, Pan JJ, Xie XJ, Chen W. Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer. Jpn J Clin Oncol. 2015;45(11):1055–63.PubMedCrossRef
33.
Zhang D, Sun G, Zhang H, Tian J, Li Y. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways. Biomed Pharmacother. 2017;85:511–6.PubMedCrossRef
34.
Liu X, Xiao ZD, Han L, Zhang J, Lee SW, Wang W, et al. LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. Nat Cell Biol. 2016;18(4):431–42.PubMedPubMedCentralCrossRef
35.
Balon TW. SGLT and GLUT: are they teammates? Focus on “mouse SGLT3a generates proton-activated currents but does not transport sugar”. Am J Physiol Cell Physiol. 2012;302(8):C1071–2.PubMedCrossRef
36.
Thorens B, Mueckler M. Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab. 2010;298(2):E141–5.PubMedCrossRef
37.
Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta. 1974;355(1):77–104.PubMed
38.
39.
Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007;67(8):3963–9.PubMedCrossRef
40.
Zou ZW, Ma C, Medoro L. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side- population stem-like cancer cells. Oncotarget. 2016;7:38.
41.
42.
43.
Liu X, Gan B. lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1. Cell cycle (Georgetown, Tex). 2016;15:3471–81.CrossRef
44.
Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med. 2004;10(7–12):65–71.PubMedPubMedCentral
45.
Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, et al. Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer. 2011;2(8):829–40.PubMedPubMedCentralCrossRef
46.
Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017;77(6):1369–82.PubMedCrossRef
47.
Sand M, Hessam S, Amur S, Skrygan M, Bromba M, Stockfleth E, et al. Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. J Dermatol Sci. 2017;86(2):142–8.PubMedCrossRef
48.
Ma MZ, Zhang Y, Weng MZ, Wang SH, Hu Y, Hou ZY, et al. Long noncoding RNA GCASPC, a target of miR-17-3p, negatively regulates pyruvate carboxylase-dependent cell proliferation in gallbladder cancer. Cancer Res. 2016;76(18):5361–71.PubMedCrossRef
49.
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, et al. Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis. Cell Rep. 2015;13(11):2395–402.PubMedPubMedCentralCrossRef
50.
Li L, Zhang Y, Qiao J, Yang JJ, Liu ZR. Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis. J Biol Chem. 2014;289(37):25812–21.PubMedPubMedCentralCrossRef
51.
Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356(2 Pt A):184–91.PubMedCrossRef
52.
Gui X, Li H, Li T, Pu H, Lu D. Long noncoding RNA CUDR regulates HULC and beta-catenin to govern human liver stem cell malignant differentiation. Mol Ther. 2015;23(12):1843–53.PubMedPubMedCentralCrossRef
53.
Li T, Zheng Q, An J, Wu M, Li H, Gui X, et al. SET1A cooperates with CUDR to promote liver cancer growth and hepatocyte-like stem cell malignant transformation epigenetically. Mol Ther. 2016;24(2):261–75.PubMedPubMedCentralCrossRef
54.
Hu P, Zheng QD, Li HY, Wu MY, An JH, et al. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc. Oncotarget. 2015;6:40775–98.
55.
Wu MY, Zheng QD, An JH, et al. Double mutant P53 (N340Q/L344R) promotes hepatocarcino- genesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Oncotarget. 2016;7:66525–39.PubMedPubMedCentral
56.
Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J, et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res. 2018.
57.
Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25(34):4683–96.PubMedCrossRef
58.
Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the “Warburg Effect” and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19(1):17–24.PubMedCrossRef
59.
Li Z, Li X, Wu S, Xue M, Chen W. Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci. 2014;105(8):951–5.PubMedPubMedCentralCrossRef
60.
Song J, Wu X, Liu F, Li M, Sun Y, Wang Y, et al. Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. Biochem Biophys Res Commun. 2017;490(2):217–24.PubMedCrossRef
61.
62.
Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017;8(1):e2569.PubMedPubMedCentralCrossRef
63.
Gao Y, Wu F, Zhou J, Yan L, Jurczak MJ, Lee HY, et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 2014;42(22):13799–811.PubMedPubMedCentralCrossRef
64.
Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101–12.PubMedCrossRef
65.
66.
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77.PubMedCrossRef
67.
Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 2010;30(2):369–74.PubMed
68.
Rawson RB. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc. 2003;70:221–31.
69.
Li D, Cheng M, Niu Y, Chi X, Liu X, Fan J, et al. Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. Int J Biol Sci. 2017;13(3):349–57.PubMedPubMedCentralCrossRef
70.
71.
Shang C, Wang W, Liao Y, Chen Y, Liu T, Du Q, et al. LNMICC promotes nodal metastasis of cervical cancer by reprogramming fatty acid metabolism. Cancer Res. 2018;78(4):877–90.PubMedCrossRef
72.
Mashek DGBK, Coleman RA, Berger J, Bernlohr DA, Black P, et al. Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res. 2004;45:1958–61.PubMedCrossRef
73.
Phillips CMGL, Bertrais S, Field MR, Cupples LA, Ordovas JM, et al. Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res. 2010;51:1973–800.
74.
Ong KT, Mashek M, Bu SY, Greenberg AS, Mashek DG. Adipose triglyc- eride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology. 2011;53:116–26.PubMedCrossRef
75.
Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330–42.PubMedCrossRef
76.
Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res. 2015;75(5):846–57.PubMedCrossRef
77.
Liu S, Xu R, Gerin I, Cawthorn WP, Macdougald OA, Chen XW, et al. SRA regulates adipogenesis by modulating p38/JNK phosphorylation and stimulating insulin receptor gene expression and downstream signaling. PLoS One. 2014;9(4):e95416.PubMedPubMedCentralCrossRef
78.
Xu B, Gerin I, Miao H, Vu-Phan D, Johnson CN, Xu R, et al. Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity. PLoS One. 2010;5(12):e14199.PubMedPubMedCentralCrossRef
79.
Liu S, Sheng L, Miao H, Saunders TL, MacDougald OA, Koenig RJ, et al. SRA gene knockout protects against diet-induced obesity and improves glucose tolerance. J Biol Chem. 2014;289(19):13000–9.PubMedPubMedCentralCrossRef
80.
Mazar J, Zhao W, Khalil AM, Lee B, et al. The functional characterization of long noncoding RNA SPRY4- IT1 in human melanoma cells. Oncotarget. 2014;5:8959–69.PubMedPubMedCentralCrossRef
81.
Zeng B, Ye HL, Chen JM, Cheng D, Cai CF, et al. LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis. Oncotarget. 2017;8:113650–61.PubMedPubMedCentral
82.
Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011;711(1–2):167–73.PubMedCrossRef
83.
Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl). 2011;89(3):229–36.CrossRef
84.
Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107(16):7455–60.PubMedPubMedCentralCrossRef
85.
Wise DR, DeBerardinisb RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. PNAS. 2008;105:18782–7.PubMedCrossRefPubMedCentral
86.
Xu XY, Li JY, Sun X, et al. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget. 2015;6:26161–76.PubMedPubMedCentral
87.
Wang X, Gao Z, Liao J, Shang M, Li X, Yin L, et al. lncRNA UCA1 inhibits esophageal squamous-cell carcinoma growth by regulating the Wnt signaling pathway. J Toxicol Environ Health A. 2016;79(9–10):407–18.PubMedCrossRef
88.
Burzio VA, Villota C, Villegas J, Landerer E, Boccardo E, Villa LL, et al. Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells. Proc Natl Acad Sci U S A. 2009;106(23):9430–4.PubMedPubMedCentralCrossRef
89.
Rackham O, Shearwood AM, Mercer TR, Davies SM, Mattick JS, Filipovska A. Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear-encoded proteins. RNA (New York, NY). 2011;17(12):2085–93.CrossRef
90.
91.
Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531(7595):518–22.PubMedCrossRef
92.
Noh JH, Kim KM, Abdelmohsen K, Yoon JH, Panda AC, Munk R, et al. HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP. Genes Dev. 2016;30(10):1224–39.PubMedPubMedCentral
93.
Vidaurre S, Fitzpatrick C, Burzio VA, Briones M, Villota C, Villegas J, et al. Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem. 2014;289(39):27182–98.PubMedPubMedCentralCrossRef
94.
Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114(10):1569–75.PubMedCrossRef
95.
Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol. 2010;30(6):1303–18.PubMedPubMedCentralCrossRef
96.
Li HJ, Sun XM, Li ZK, Yin QW, Pang H, Pan JJ, et al. LncRNA UCA1 promotes mitochondrial function of bladder cancer via the MiR-195/ARL2 signaling pathway. Cell Physiol Biochem. 2017;43(6):2548–61.PubMedCrossRef
97.
Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27(7):728–35.PubMedCrossRef
98.
Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci US A. 2003;100(12):7111–6.CrossRef
99.
Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. J Clin Invest. 2016;126(11):4205–18.PubMedPubMedCentralCrossRef
100.
Shimizu SNM, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483–7.PubMedCrossRef
101.
MiaoW T, Gang L. long non-coding RNA MEG3 induces renal cell carcinoma cells apoptosis by activating the mitochondrial pathway J Huazhoung Univ sci Technol 2015;35:541–545.
102.
Kong LZX, Wu Y. Targeting HOTAIR induces mitochondria related apoptosis and inhibits tumor growth in head and neck aquamous cell carcinoma in vitro and invivo. Curr Mol Med. 2015;15:952–60.PubMedCrossRef
103.
Wei YF, Yu ST, Zhang YP, et al. NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer. Oncotarget. 2017;8:29038–47.PubMedPubMedCentral
104.
105.
Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta. 2010;1803(4):443–51.PubMedCrossRef
106.
Shi J, Dong B, Cao J, Mao Y, Guan W, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget. 2017;8:27582–92.PubMedPubMedCentral
107.
Luo F, Liu X, Ling M, Lu L, Shi L, Lu X, et al. The lncRNA MALAT1, acting through HIF-1alpha stabilization, enhances arsenite-induced glycolysis in human hepatic L-02 cells. Biochim Biophys Acta. 2016;1862(9):1685–95.PubMedCrossRef
108.
Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell. 2014;53(1):88–100.PubMedCrossRef
109.
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275(29):21797–800.PubMedCrossRef
110.
White MA, Lin C, Rajapakshe K, Dong J, Shi Y, Tsouko E, et al. Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer. Mol Cancer Res. 2017;15(8):1017–28.
111.
Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014;111(52):18697–702.PubMedPubMedCentralCrossRef
112.
Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. NPNAS. 2000;97:12216–21.
113.
Wang O, Yang F, Liu Y, Lv L, Ma R, et al. C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. Am J Transl Res. 2017;9:533–45.PubMedPubMedCentral
114.
Liu PY, Atmadibrata B, Mondal S, Tee AE, Liu T. NCYM is upregulated by lncUSMycN and modulates N-Myc expression. Int J Oncol. 2016;49(6):2464–70.PubMedCrossRef
115.
Shen C, Jr WGK. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23:18–25.PubMedCrossRef
116.
Zhai W, Sun Y, Jiang M, Wang M, Gasiewicz TA, Zheng J, et al. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2alpha/C-MYC axis under hypoxia. Oncogene. 2016;35(37):4866–80.PubMedCrossRef
117.
Miyamoto T, Lo PHY, Saichi N, Ueda K. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Mol Biol. 2017;3(5):e1603204.
118.
Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. J Biol Chem. 1997;272:22776–80.PubMedCrossRef
119.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–20.PubMedCrossRef
120.
Stambolic V, MacPherson D, Sas D, Lin Y, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317–25.PubMedCrossRef
121.
Matoba S, Kang JG, Patino WD, et al. P53 regulates mitochondrial respiration. Science (New York, NY). 2006;312:1650–3.CrossRef
122.
Schmitt AM, Garcia JT, Hung T, Flynn RA, Shen Y, Qu K, et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet. 2016;48(11):1370–6.PubMedPubMedCentralCrossRef
123.
Jiang X, Liu W. Long noncoding RNA highly upregulated in liver cancer activates p53-p21 pathway and promotes nasopharyngeal carcinoma cell growth. DNA Cell Biol. 2017;36(7):596.
124.
Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin H, et al. HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. Biomed Pharmacother. 2017;90:555–61.PubMedCrossRef
125.
Su P, Wang F, Qi B, Wang T, Zhang S. P53 regulation-association long non-coding RNA (LncRNA PRAL) inhibits cell proliferation by regulation of P53 in human lung cancer. Med Sci Monit. 2017;23:1751–8.PubMedPubMedCentralCrossRef
126.
Wang B, Jiang H, Wang L, Chen X, Wu K, Zhang S, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 2017;13(5):3494–500.PubMedPubMedCentralCrossRef
127.
128.
Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9.PubMedCrossRef
129.
Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15(3):521–9.PubMedCrossRef
130.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.PubMedCrossRef
131.
Li Y, Lin X, Zhao X, Xie J, JunNan W, Sun T, et al. Ozone (O3) elicits neurotoxicity in spinal cord neurons (SCNs) by inducing ER ca(2+) release and activating the CaMKII/MAPK signaling pathway. Toxicol Appl Pharmacol. 2014;280(3):493–501.PubMedCrossRef
132.
Yang C, Li X, Wang Y, Zhao L, Chen W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene. 2012;496(1):8–16.PubMedCrossRef
133.
Zheng Q, Lin Z, Li X, Xin X, Wu M, An J, et al. Inflammatory cytokine IL6 cooperates with CUDR to aggravate hepatocyte-like stem cells malignant transformation through NF-kappaB signaling. Sci Rep. 2016;6:36843.PubMedPubMedCentralCrossRef
134.
Feng Y, Zou W, Hu C, Li G, Zhou S, He Y, et al. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys. 2017;623-624:20–30.PubMedCrossRef
135.
Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, et al. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Gene. 2017;607:41–6.PubMedCrossRef
136.
Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122–8.PubMedCrossRef
137.
Chen YX, Yu W, Le Z, Wei C. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene. 2012;496:8–16.PubMedCrossRef
138.
Sun LC, Jiang CH, Xu CJ, et al. Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway. Oncotarget. 2017;8:27929–42.PubMedPubMedCentral
139.
Gong J, Qi X, Zhang Y, Yu Y, Lin X, Li H, et al. Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression. Biomed Pharmacother. 2017;93:40–7.PubMedCrossRef
140.
141.
142.
Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene. 2008;27(55):6908–19.PubMedCrossRef
143.
Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, et al. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest. 2016;126(6):2267–79.PubMedPubMedCentralCrossRef
144.
145.
Kasomva K, Sen A, Paulraj MG, et al. Roles of microRNA on cancer cell metabolism. J Transl Med. 2012;10:228.CrossRef
146.
Luo FLX, Ling M, Lu L, Shi L, Lu X, et al. The lncRNA MALAT1, acting through HIF-1alpha stabilization, enhances arsenite-induced glycolysis in human hepatic L-02 cells. Biochim Biophys Acta. 1862;2016:1865–95.
147.
Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMedCrossRef
148.
Fei X, Qi M, Wu B, Song Y, Wang Y, Li T. MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett. 2012;586(4):392–7.PubMedCrossRef
149.
Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507(2):135–8.PubMedCrossRef
150.
Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol. 2011;31(13):2696–706.PubMedPubMedCentralCrossRef
151.
Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn. 2010;12(4):433–40.PubMedPubMedCentralCrossRef
152.
MengF H, Janek HW. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.CrossRef
153.
Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-Oncology. 2010;12(11):1102–12.PubMedPubMedCentralCrossRef
154.
Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2009;16(1):23–9.PubMedCrossRef
155.
Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol. 2011;332(1–2):125–33.PubMedCrossRef
156.
Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620–32.PubMedPubMedCentralCrossRef
157.
Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009;69(14):5761–7.PubMedCrossRef
158.
Lynn FC. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab. 2009;20(9):452–9.PubMedCrossRef
159.
Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48(6):1810–20.PubMedCrossRef
160.
Jin LH, Xu L, Pang H, Pan JJ, Xie XJ, Chen W. Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer. Jpn J Clin Oncol. 2015;45:1055–63.CrossRef
161.
Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A. 2012;109(23):8983–8.PubMedPubMedCentralCrossRef
162.
Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10(1):67.PubMedPubMedCentralCrossRef
163.
Lin H, Zhang X, Feng N, Wang R, Zhang W, Deng X, et al. LncRNA LCPAT1 mediates smoking/particulate matter 2.5-induced cell autophagy and epithelial-mesenchymal transition in lung cancer cells via RCC2. Cell Physiol Biochem. 2018;47(3):1244–58.PubMedCrossRef
164.
Gu Z, Hou Z, Zheng L, Wang X, Wu L, Zhang C. LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5. Biomed Pharmacother. 2018;104:110–8.PubMedCrossRef
165.
Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014;11(1):1–19.PubMedPubMedCentral
166.
167.
Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, et al. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science (New York, NY). 2012;338(6109):956–9.CrossRef
168.
Liu C, Zhang Y, She X, Fan L, Li P, Feng J, et al. A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy. J Hematol Oncol. 2018;11(1):77.PubMedPubMedCentralCrossRef
169.
Kang YH, Kim D, Jin EJ. Down-regulation of phospholipase D stimulates death of lung cancer cells involving up-regulation of the long ncRNA ANRIL. Anticancer Res. 2015;35:2795–804.PubMed
170.
Liu YM, Ma JH, Zeng QL, Lv J, Xie XH, Pan YJ, et al. MiR-19a affects hepatocyte autophagy via regulating lncRNA NBR2 and AMPK/PPARalpha in D-GalN/lipopolysaccharide-stimulated hepatocytes. J Cell Biochem. 2018;119(1):358–65.PubMedCrossRef
171.
Li T, Sun XZ, Jiang XH. UCA1 involved in the metformin- regulated bladder cancer cell proliferation and glycolysis. Tumor Biol. 2017;39(6):1010428317710823.
172.
Zhou Q, Chen FL, Jl Z. Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. Oncotarget. 2016;7(50):82620–33.PubMedPubMedCentral
173.
174.
Li X, Wu Z, Fu X, Han W. lncRNAs: insights into their function and mechanics in underlying disorders. Mutat Res Rev Mutat Res. 2014;762:1–21.PubMedCrossRef
175.
Liu FY, Chao A, Lai CH, Chou HH, Yen TC. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012;125(3):566–71.PubMedCrossRef
176.
Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25(6):406–13.PubMedCrossRef
177.
Wang C, Mao ZP, Wang L, Wu GH, Zhang FH, Wang DY, et al. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway. Neoplasma. 2017;64(5):725–31.
Metadata
Title
Emerging roles of long non-coding RNAs in tumor metabolism
Authors
Hui Sun
Zhaohui Huang
Weiqi Sheng
Mi-die Xu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0648-7

Other articles of this Issue 1/2018

Journal of Hematology & Oncology 1/2018 Go to the issue

Case report

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Research

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways

Research

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine

Research

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis

Review

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Review

BCL-2 as therapeutic target for hematological malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits